The combination of exosomal SP-B&CAPN2 was able to distinguish CTD-ILD from the control groups when serum KL-6 levels were undetectable; no existing CTD-ILD biomarkers can rival this level of accuracy. This evidence concerns the gene SFTPB and interstitial lung disease.